Trial Profile

A Window of Opportunity Trial of Onapristone as Preoperative Treatment for Postmenopausal Women With Hormone Receptor-Positive and HER2-negative Breast Cancer

Status: Completed

Phase of Trial: Phase 0

Latest Information Update: 06 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Onapristone (Primary)
Indications Early breast cancer; HER2 negative breast cancer
Focus Biomarker; Therapeutic Use
Acronyms ONAWA; Onward 203

Most Recent Events

31 Mar 2022 Status changed from recruiting to completed.
09 Dec 2021 According to a Context Therapeutics media release, results from this trial were presented during the 2021 San Antonio Breast Cancer Symposium (SABCS).
09 Dec 2021 Positive results published in the Context Therapeutics Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com